PDS Biotechnology (NASDAQ:PDSB) Releases Quarterly Earnings Results

PDS Biotechnology (NASDAQ:PDSB) issued its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08, Zacks reports.

PDS Biotechnology Trading Up 0.8 %

NASDAQ:PDSB traded up $0.01 during mid-day trading on Thursday, reaching $1.25. 252,152 shares of the company’s stock traded hands, compared to its average volume of 551,315. The company has a 50 day moving average price of $1.41 and a 200-day moving average price of $2.18. The firm has a market capitalization of $47.74 million, a price-to-earnings ratio of -1.08 and a beta of 1.68. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. PDS Biotechnology has a 12-month low of $1.13 and a 12-month high of $4.56.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their target price on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.